Syngene’s new biologics facility in the U.S.
Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers. The addition of this facility increases Syngene’s total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.
Neutralizing antibody assay for a fully human PD-1 blocking monoclonal antibody
Learn how Syngene’s PD-1 neutralizing antibody bioassay reduced donor variability and drug interference for immunogenicity assessment. Read the full case study today.
Reimagining CROs: Integrated Innovation Partnerships as the Future of Drug Discovery
Eroom’s Law highlights a troubling trend in pharmaceutical R&D: the cost and time required to develop new drugs have been steadily increasing despite technological advances (1). As a result, drug discovery is under constant pressure.
Immunogenicity assay for an RNAi therapeutic (small interfering RNA) on the MSD platform
Syngene’s MSD-based ADA assay enabled sensitive, drug-tolerant immunogenicity assessment for a clinical siRNA therapeutic in regulated studies. Learn more.
Improving Supply Chain Resilience: HPAPI Containment And Batch Reliability In Global Pharma Manufacturing
Global pharmaceutical supply chains are under sustained pressure from rising regulatory expectations, complex molecules, and frequent disruptions across geographies. For manufacturers handling highly potent active pharmaceutical ingredients (HPAPIs), the challenge is more pronounced.
Global Clinical Trials: How Strategic Partnerships and Emerging Markets Are Shaping the Future of Inclusive Research
Clinical trials sit at the heart of modern drug development. They are the bridge between promising science and real-world patient benefit. Yet the way trials are planned and executed has changed sharply in the last decade. Sponsors are dealing with complex biologics, precision medicines, combination therapies, and indications where standard endpoints are evolving.
Frost & Sullivan Report on Redefining Value in Biologics Outsourcing Partnerships
Frost & Sullivan Report on Redefining Value in Biologics Outsourcing Partnerships – Discover the latest trends, challenges, and strategic insights shaping the future of biologics outsourcing partnerships.
Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It’s Essential for Success
Publication: Fierce Biotechnology
Pharmacokinetics-focused bioanalysis for a half-life extended bispecific antibody in oncology
See how Syngene used MSD platform pharmacokinetics and immunogenicity assays to de-risk a half-life extended bispecific antibody in oncology. Explore the case study.
BIOSECURE Act 2025 update: what it means for biopharma outsourcing and what to do now
Publication: Pharmaceutical Technology Focus